arrow
M

Martine E.D. Chamuleau

Amsterdam University Medical Centers
H指数:27
被引数:3,084

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Nivolumab consolidation in patients with double and triple hit high-grade B-cell lymphoma in complete metabolic remission after DA-EPOCH-R

Nivolumab巩固治疗在完成DA-EPOCH-R方案后达到完全代谢缓解的双打击和三打击高危B细胞淋巴瘤患者中的应用

2026-10-300
OA
Molecular Profiling and Disease Tracking of Post-transplant Lymphoproliferative Disorders using Cell-free DNA

利用游离DNA进行移植后淋巴增生性疾病的分子分型和疾病追踪

2026-08-280
OA
Predicting 2-year time to progression in diffuse large B cell lymphoma using 3D CNNs on whole-body PET/CT scans

使用3D CNNs在全身PET/CT扫描上预测弥漫性大B细胞淋巴瘤的2年进展时间

2025-11-280
OAAI
Cytoskeletal dynamics and mitochondrial rearrangements drive cell fate upon antibody-induced complement activation in DLBCL

细胞骨架动力学和线粒体重排驱动弥漫大B细胞淋巴瘤中抗体诱导的补体激活后的细胞命运

2025-10-060
OA
Rationale and design of the HOVON 170 DLBCL-ANTICIPATE trial: preventing anthracycline-induced cardiac dysfunction with dexrazoxane

HOVON 170 DLBCL-预期试验的原理和设计: 用右雷佐生预防蒽环类药物诱导的心功能障碍

2025-01-280
OAAI
Clinical characteristics and survival outcomes of patients with primary central nervous system lymphoma treated with high-dose methotrexate-based polychemotherapy and consolidation therapies
2024-12-010
PRE
Immunosuppressed Tumor Microenvironment in MYC-Rearranged High-Grade B-Cell Lymphomas Compared to Diffuse Large B-Cell Lymphomas, Not Otherwise Specified

MYC重排的高级别B细胞淋巴瘤与未特别指明的弥漫性大B细胞淋巴瘤相比的免疫抑制性肿瘤微环境

BLOOD
IF23.1
2024-11-050
PRE
Validation of an Artificial Intelligence-Based Prediction Model Using 5 External PET/CT Datasets of Diffuse Large B-Cell Lymphoma

基于人工智能的预测模型验证:使用5个外部PET/CT数据集的弥漫性大B细胞淋巴瘤

2024-10-033
PRE
Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study

Epcoritamab单药治疗复发性或难治性滤泡性淋巴瘤患者 (EPCORE NHL-1): 单臂多中心研究的2期队列

2024-08-018
PRE
R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma (HOVON/SAKK): final results of a multicentre, phase 3, open-label, randomised trial
2023-12-015
OAAI
Genomic profiling of post-transplant lymphoproliferative disorders using cell-free DNA
2023-09-144
OAAI